Pfizer's Latest Immunotherapy Deal Could Be Great News for This Tiny Company

Pfizer's Latest Immunotherapy Deal Could Be Great News for This Tiny Company·Motley Fool

There's renewed interest in an immuno-oncology target that just so happens to match Agenus' lead (unpartnered) drug candidate.

Advertisement